Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Vasculitis Clear all

Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG), Microscopic Polyangiitis (MPA), ANCA-Associated Vasculitis (AAV), Vasculitis
Interventions: Online questionnaire; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Interventions: NKX019, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Plantation, Florida • Tampa, Florida + 9 more

Conditions: Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis
Interventions: milatuzumab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: West Hollywood, California

Conditions: Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
Interventions: CryoSpray Ablation; Device
Lead sponsor: CSA Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions: IFX-1 low dose, IFX-1 high dose, Placebo; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 33
States / cities: Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Retinoic acid, Standard of care; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Churg Strauss Syndrome
Interventions: Mepolizumab; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Povetacicept; Drug
Lead sponsor: Alpine Immune Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more

Conditions: Wegener's Granulomatosis
Interventions: Abatacept; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions: ADI-001, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Buffalo, New York

Conditions: Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions: prednisone and methotrexate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions: Mepolizumab, Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more

Conditions: Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Interventions: AB-101, Rituximab, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: IRIS Research and Development, LLC; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Standard of care treatment, eculizumab; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Eosinophilic Granulomatous Vasculitis
Interventions: Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more

Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions: FT819, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 16
States / cities: Beverly Hills, California • Fullerton, California • Irvine, California + 13 more

Conditions: Asthma, Hypersensitivity, Lung Diseases, Wegener's Granulomatosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: Reslizumab; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions: Abatacept, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 15 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: 1 Year to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CC-97540, Lymphodepletion Chemotherapy; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ANCA-associated Vasculitis
Interventions: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions: Observational; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more

Search by objective public record fields.

The ANCA Vasculitis Questionnaire (AAV-PRO©)

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Phase Ib Study of SC Milatuzumab in SLE

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens

Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

Steroids and Methotrexate to Treat Systemic Vasculitis

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study